Powered By

Seattle Genetics And Agensys, An Affiliate Of Astellas, Announce Initiation Of Phase I Clinical Trial Of ASG-5ME For ...


Published:Thu, 22 Jul 2010 05:29:11 -0700 
Seattle Genetics, Inc. (Nasdaq:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. There is significant need for new ......

Read More...


del.icio.us      |  Digg   |  Reddit   |   Add to Mixx!


More Articles